Cedars-Sinai Cancer Experts To Present Clinical Findings at AACR Conference

Newswise — LOS ANGELES (April 11, 2023) -- Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.

Select experts and topics include:

• Lung cancer: Efficacy and safety of adjuvant atezolizumab from the Phase 2 LCMC3 study; the prognostic impact of the KRAS G12C-mutation in non-small cell lung cancer; and clinical characteristics, real-world treatment patterns, and clinical outcomes among patients with previously treated metastatic or unresectable EGFR-mutated non-small cell lung cancer in the United States.
  Expert: Karen Reckamp, MD, director of Medical Oncology at Cedars-Sinai Cancer
   
• Solid Tumors: Late-breaking results from the targeted agent and profiling utilization registry study: temsirolimus in patients with solid tumors with PTEN mutation.
  Expert: Kristopher Wentzel, MD, oncologist at The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate
   
• Prostate cancer: Targeting androgen receptor coregulators to enhance enzalutamide sensitivity in prostate cancer.
  Expert: Moray Campbell, PhD, research scientist at Cedars-Sinai Cancer
   
• Pancreatic cancer: Suppression of phosphorylated focal adhesion kinase + fibroblasts and C-X-C chemokine receptor type 4 expressing granulocytes is associated with exceptional clinical outcomes in pancreatic ductal adenocarcinoma.
  Expert: Arsen Osipov, MD, program lead in the Pancreatic Cancer Multidisciplinary Clinic and Precision Medicine Program at Cedars-Sinai Cancer
   
• Melanoma: Intratumoral MEDI1191 + durvalumab: Update on the first-in-human study in advanced solid tumors.
  Expert: Omid Hamid, MD, director of the Melanoma Center at The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate
   
• Melanoma: Neoadjuvant pembrolizumab and vibostolimab or gebasaxturev or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma.
  Expert: Inderjit Mehmi, MD, oncologist at Cedars-Sinai Cancer
   
• Glioblastoma: Brain delivery of clinically suitable nanobioconjugates to inhibit glioblastoma growth through extracellular matrix-immune cell crosstalk.
  Expert: Alexander Ljubimov, PhD, professor of Biomedical Sciences and Neurosurgery
   
• Sarcoma: Circular RNAs repress interferon responses in the sarcoma cells and promote sarcoma growth by forging a pro-tumorigenic immune microenvironment.
  Expert: Jlenia Guarnerio, PhD, MS, assistant professor of Radiation Oncology

Interviews can be arranged in-person, or by using most virtual meeting formats, including Zoom, FaceTime and Skype.